FDA Halts Newron's Phase III Schizophrenia Trial Following Patient Death
核心洞察
The FDA has placed a clinical hold on enrollment for Newron Pharmaceuticals (搜索)' Phase III ENIGMA-TRS 2 trial of evenamide in treatment-resistant schizophrenia following a patient death at a non-US clinical site.
Evenamide represents a first-in-class, glutamate (搜索)-modulating add-on antipsychotic that differs mechanistically from existing dopamine-targeting therapies for treatment-resistant schizophrenia.
While an investigator deemed the death unrelated to study treatment, the trial remains on hold pending FDA review, though the parallel ENIGMA-TRS 1 study continues with over 400 patients enrolled across 21 countries.
The US Food and Drug Administration has placed a clinical hold on enrollment for Newron Pharmaceuticals (搜索)' Phase III ENIGMA-TRS 2 study of evenamide in treatment-resistant schizophrenia following a patient death at a clinical site outside the United States. The regulatory action highlights the heightened scrutiny surrounding psychiatric drug development and the challenges facing novel therapeutic approaches in this underserved patient population.
Clinical Hold Details and Company Response
The FDA imposed the hold on the late-stage ENIGMA-TRS 2 study (NCT04461119) after Newron informed the agency of a study participant's sudden death. Newron has not publicly disclosed the cause of the patient's death, though an investigator deemed the fatality unrelated to the study treatment.
Despite the investigator's assessment, the trial will remain on hold pending FDA review. Ravi Anand, Newron's Chief Medical Officer, stated in a 29 April announcement that "there is no increase in the risk of mortality between the drug- and placebo-treated patients based on the duration of treatment" in the evenamide development program to date. Anand also noted that sudden death is "unfortunately not uncommon in patients with schizophrenia."
Following the event, Newron consulted with the independent international safety monitoring board for the ENIGMA-TRS program, which recommended that both studies continue as originally designed. While US enrollment for ENIGMA-TRS 2 remains paused, the parallel ENIGMA-TRS 1 study (EUCT2024-519836-18-00) continues operations and has enrolled more than 400 patients across 21 countries.
Evenamide's Novel Mechanism of Action
Evenamide, also designated as NW-3509, represents a first-in-class, add-on antipsychotic pill specifically designed for treatment-resistant schizophrenia. The drug distinguishes itself through its modulation of glutamate (搜索) neurotransmission, contrasting with approved alternatives that predominantly target dopamine pathways. This mechanistic differentiation positions evenamide as a potentially important therapeutic option in a space where dopamine-targeting drugs have dominated for decades.
The drug's glutamatergic approach addresses excessive glutamate (搜索) release through sodium channel (搜索) modulation, offering a mechanistically distinct strategy for patients inadequately controlled on existing antipsychotics.
Significant Unmet Medical Need
Treatment-resistant schizophrenia represents a substantial area of unmet medical need within psychiatric care. Researchers estimate that approximately 30% of schizophrenia patients have treatment-resistant disease, yet only one FDA-approved medicine, clozapine, is specifically indicated for this condition. Clozapine received regulatory approval nearly four decades ago, underscoring the limited therapeutic advancement in this patient population.
The broader schizophrenia research landscape currently includes 57 ongoing Phase III trials, reflecting continued industry investment in addressing these unmet needs. Recent regulatory activity includes the FDA's approval of a label expansion for Johnson & Johnson's Caplyta (lumateperone) for schizophrenia relapse prevention, and Bristol Myers Squibb (搜索)'s Cobenfy (xanomeline/trospium chloride), which recently secured US regulatory approval though initial uptake has been slow due to insurance challenges and prescriber reluctance.
Regulatory Implications and Program Outlook
The FDA's decision to impose a full clinical hold rather than a partial hold or request for additional safety data suggests specific regulatory concerns about the nature or circumstances of the death. This regulatory response carries significant implications for the program's timeline and the company's ability to advance evenamide through the approval process.
The clinical hold triggers immediate obligations to notify enrolled US participants and halt new dosing or randomization domestically. The duration of the hold will likely depend on the FDA's formal assessment of the death's relationship to evenamide treatment and the adequacy of the study's safety monitoring procedures.